About: Human Monoclonal Antibodies from Transgenic Mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Human Monoclonal Antibodies from Transgenic Mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Human Monoclonal Antibodies from Transgenic Mice
Creator	Lonberg, N
Source	PMC
abstract	Since the 1986 regulatory approval of muromonomab-CD3, a mouse monoclonal antibody (MAb) directed against the T cell CD3ε antigen, MAbs have become an increasingly important class of therapeutic compounds in a variety of disease areas ranging from cancer and autoimmune indications to infectious and cardiac diseases. However, the pathway to the present acceptance of therapeutic MAbs within the pharmaceutical industry has not been smooth. A major hurdle for antibody therapeutics has been the inherent immunogenicity of the most readily available MAbs, those derived from rodents. A variety of technologies have been successfully employed to engineer MAbs with reduced immunogenicity. Implementation of these antibody engineering technologies involves in vitro optimization of lead molecules to generate a clinical candidate. An alternative technology, involving the engineering of strains of mice to produce human instead of mouse antibodies, has been emerging and evolving for the past two decades. Now, with the 2006 US regulatory approval of panitumumab, a fully human antibody directed against the epidermal growth factor receptor, transgenic mice expressing human antibody repertoires join chimerization, CDR grafting, and phage display technologies, as a commercially validated antibody drug discovery platform. With dozens of additional transgenic mouse-derived human MAbs now in clinical development, this new drug discovery platform appears to be firmly established within the pharmaceutical industry.
has issue date	2008-01-01(xsd:dateTime)
bibo:doi	10.1007/978-3-540-73259-4_4
bibo:pmid	18071942
has license	no-cc
sha1sum (hex)	037cf8ad7f5ab3cb10dfabaa9aabfaa7d15313d6
schema:url	https://doi.org/10.1007/978-3-540-73259-4_4
resource representing a document's title	Human Monoclonal Antibodies from Transgenic Mice
has PubMed Central identifier	PMC7120671
has PubMed identifier	18071942
schema:publication	Therapeutic Antibodies
resource representing a document's body	covid:037cf8ad7f5ab3cb10dfabaa9aabfaa7d15313d6#body_text
is schema:about of	named entity 'TRANSGENIC MICE' named entity 'HUMAN' named entity 'MONOCLONAL ANTIBODIES' named entity 'Human Monoclonal Antibodies' named entity 'antibody' named entity 'antibody' named entity 'affinity maturation' named entity 'IgG1' named entity 'ofatumumab' named entity 'peptide' named entity 'Bleeker' named entity 'immunoglobulin' named entity 'preclinical' named entity 'immunogenic' named entity 'transgenic mouse' named entity 'mice' named entity 'Transgenic mice' named entity 'clinical testing' named entity 'protein' named entity 'yeast artificial chromosome' named entity 'light-chain' named entity 'Fc-receptor' named entity 'ipilimumab' named entity 'hybridoma' named entity 'rodent' named entity 'CD16' named entity 'loading dose' named entity 'light-chain' named entity 'cell development' named entity 'generation time' named entity 'transgenic mice' named entity 'chimeric' named entity 'ipilimumab' named entity 'MAb' named entity 'high affinity' named entity 'antigens' named entity 'loci' named entity 'gene' named entity 'CNTO 1275' named entity 'NHL' named entity 'half-life' named entity 'drug tolerability' named entity 'antibodies' named entity 'light-chain' named entity 'adverse events' named entity 'light chain' named entity 'transgene' named entity 'subcutaneous' named entity 'human gene sequences' named entity 'Clostridium difficile' named entity 'human chromosome' named entity 'endogenous' named entity 'ipilimumab' named entity 'antibody' named entity 'postmenopausal women' named entity 'basic research' named entity 'immunogenicity' named entity 'clinical testing' named entity 'immune response' named entity 'rodent' named entity 'mice' named entity 'antibodies' named entity 'heavy chain' named entity 'cetuximab' named entity 'antibody' named entity 'molecule' named entity 'heavy chains' named entity 'Bleeker' named entity 'MAbs' named entity 'transgenic' named entity 'panitumumab' named entity 'antigens' named entity 'antibody' named entity 'CTLA-4' named entity 'rituximab' named entity 'Panitumumab' named entity 'phage display' named entity 'ofatumumab' named entity 'transgenes' named entity 'EGFR' named entity 'muromonab-CD3'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software